Table 1.
Comparison of possible demographic and clinical parameters of patients with perimesencephalic and non-perimesencephalic patterns of hemorrhage.
| PMSAH | nPMSAH | p value | |
|---|---|---|---|
| Total (%) | 39 (53) | 35 (47) | |
| Demographic (%) | |||
| Age (median, years) | 55 (47–62) | 60 (53–65) | 0.103 |
| Gender | 0.53 | ||
| Male | 24 (32) | 24 (32) | |
| Female | 15 (20) | 11 (15) | |
| Risk factors (%) | |||
| Hypertension | 8 (21) | 7 (20) | 0.957 |
| Smoking | 12 (31) | 5 (14) | 0.095 |
| Coagulation-influencing drugs | 0.020c | ||
| aAntiplatelet therapy | 3 (8) | 5 (14) | 0.246 |
| Dietary supplements | 1 (6) | 6 (17) | 0.025c |
| Alcohol | 1 (6) | 0 (0) | – |
| bDrug use | 0 (0) | 1 (3) | – |
| Clinical condition at admission (%) | |||
| HH | 0.027c | ||
| Grade 1 or 2 | 38 (97) | 26 (74) | |
| Grade 3, 4 or 5 | 1 (6) | 9 (26) | |
| WFNS | 0.014c | ||
| Grade 1 or 2 | 39 (100) | 28 (80) | |
| Grade 3, 4 or 5 | 0 (0) | 7 (20) | |
| Clinical manifestations (%) | |||
| Nausea/vomiting | 22 (56) | 19 (54) | – |
| Loss of consciousness | 1 (8) | 6 (17) | – |
| Ocular nerve palsy | 0 (0) | 3 (9) | – |
| Seizure | 0 (0) | 1 (3) | – |
| Clinical events attributable to SAH (%) | |||
| Hydrocephalus | 2 (5) | 20 (57) | <0.0001d |
| Vasospasms | 3 (8) | 9 (26) | 0.069 |
| VP-shunt | 2 (5) | 9 (26) | 0.014c |
| Outcomes at discharge (%) | |||
| GOS | 0.073 | ||
| 1–2 | 39 (100) | 32 (91) | |
| 3–5 | 0 (0) | 3 (9) | |
| mRS | 0.267 | ||
| 0–2 | 39 (100) | 31 (89) | |
| 3–6 | 0 (0) | 4 (11) | |
PMSAH: perimesencephalic subarachnoid hemorrhage; nPMSAH: non-perimesencephalic subarachnoid hemorrhage; HH: Hunt-Hess; WFNS: World Federation of Neurological Surgeons; VP: ventriculoperitoneal; GOS: Glasgow Outcome Scale; mRS: modified Rankin Scale.
a
Coagulation-influencing drugs included aspirin and clopidogrel.
b
Cocaine abuse.
c
Significant p value below 0.05.
d
Significant p value below 0.01.